原发性胶质母细胞瘤患者放疗反应相关癌症遗传标志物——面向精准医学的放射基因组学方法
研究纳入2009年1月至2016年12月161例新诊断IDH野生型胶质母细胞瘤患者,均接受手术及Stupp方案辅助同步放化疗,其中49例术后MRI有可测量病灶者纳入分析。按RANO标准评估放疗反应,比较进展组与非进展组的基因组差异。结果显示CDKN2A缺失、EGFR突变及免疫相关基因集富集可能与放疗反应相关。
要点
- 49例可评估患者中放疗反应为非进展22例(44.9%)、进展27例(55.1%),3个月后7例进展者表现为假性进展。
- 校正假性进展后,真非应答组与真应答组1年无进展生存率分别为0%与45.4%(p<0.001)。
- 真非应答组CDKN2A缺失(94.4% vs 55.6%,p=0.013)和EGFR突变(33.3% vs 3.7%,p=0.012)多于真应答组。
核心结论
- RANO标准可用于放疗短期反应评估,但需考虑假性进展。
- CDKN2A缺失、EGFR突变及免疫或炎症相关基因集富集可能是放疗反应的潜在预测标志物。
研究设计与样本
- 2009年1月至2016年12月,161例新诊断IDH野生型胶质母细胞瘤患者接受手术及Stupp方案辅助同步放化疗,对其手术标本进行基因组研究。
- 161例中49例术后MRI有临床可测量病灶者纳入分析,按RANO标准评估放疗反应。
- 采用Fisher检验比较进展与非进展患者的DNA突变和拷贝数改变,并行基因集富集分析(GSEA)。
主要发现
- 放疗反应为非进展22例(44.9%)、进展27例(55.1%),3个月后7例进展者表现为假性进展。
- 校正假性进展后,真非应答组与真应答组1年无进展生存率分别为0%与45.4%(p<0.001),总生存率分别为52.5%与81.1%(p=0.046)。
- 真非应答组较真应答组CDKN2A缺失更多(94.4% vs 55.6%,p=0.013),EGFR突变更多(33.3% vs 3.7%,p=0.012),TP53突变更少(22.2% vs 40.7%,p=0.333)。
- GSEA显示免疫相关基因集在真非应答组富集,而部分细胞周期相关基因集在真应答组富集。
关键数值与推荐
- 放疗反应评估采用RANO标准。
- 真非应答组与真应答组1年无进展生存率分别为0%与45.4%(p<0.001),总生存率分别为52.5%与81.1%(p=0.046)。
- 真非应答组与真应答组CDKN2A缺失分别为94.4%与55.6%(p=0.013),EGFR突变分别为33.3%与3.7%(p=0.012),TP53突变分别为22.2%与40.7%(p=0.333)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To find genetic markers associated with response to radiotherapy (RT) in glioblastoma (GB) patients. MATERIALS AND METHODS: From Jan 2009 to Dec 2016, 161 patients with newly diagnosed IDH-wild type GB were treated with surgery and adjuvant concurrent chemoradiotherapy with the Stupp's regimen, and then genomic research proceeded with their surgical specimens. Among the 161 patients, 49 with clinically measurable disease on postoperative MRI were analyzed. The response evaluation to RT was based on Response Assessment in Neuro-Oncology (RANO) criteria. For genomic analyses to compare between patients with progression and non-progression, Fisher test for DNA mutations and copy number alterations and the Gene Set Enrichment Analysis (GSEA) were performed. RESULTS: RT responses were non-progressive and progressive disease (PD) in 22 (44.9%) and 27 patients (55.1%), respectively. After three months, seven of PD exhibited pseudoprogression. For true response adjusting pseudoprogression from PD, 1-year progression-free survival for true Non-Responders (tNR-group) and true Responders (tR-group) were 0% and 45.4% (p < 0.001), and overall survival were 52.5% and 81.1% (p = 0.046), respectively. In genomic analyses, the tNR-group had more CDKN2A deletions (94.4% vs. 55.6%, p = 0.013), EGFR mutations (33.3% vs. 3.7%, p = 0.012) and less TP53 mutations (22.2% vs. 40.7%, p = 0.333) than the tR-group. In GSEA, immune-related gene sets were enriched in the tNR-group, and in contrast, some gene sets related with cell cycle were enriched in tR-groups. CONCLUSION: The RANO criteria were feasible for the short-term response evaluation from RT despite of pseudoprogression. Genomic differences such as CDKN2A deletion, EGFR mutation, and immune- or inflammation-related related gene sets enrichment were found to be potentially predictive markers of RT.
引用
- Yang K, Jung SW, Shin H, et al. Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma - Radiogenomic approach for precision medicine. Radiother Oncol. 2018. PMID: 30773189. doi:10.1016/j.radonc.2018.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。